Manish Goel

About Manish Goel

SEBI Registered Research Analyst • Chartered Accountant

377 Articles Published

Manish Goel is a Chartered Accountant, SEBI Registered Research Analyst, and founder of Manish Goel PMS. A full-time value investor since 2010, he has helped thousands of investors build long-term wealth through quality stock picking and disciplined fundamental analysis.

Facebook X (Twitter) Instagram YouTube LinkedIn

May 21, 2026

Infographic: Negativity Bias with four quadrants—Lucky (gray), DISCIPLINED INVESTOR (green), Confused (light gray), BIAS-TRAPPED (orange) on a dark blue background.

Negativity Bias: Baumeister, Bratslavsky, Finkenauer & Vohs (2001) ‘Bad Is Stronger Than Good’

Roy Baumeister and colleagues showed in 2001 that bad events register roughly three times more strongly than good ones in the human mind. For Indian retail investors, this asymmetry explains panic selling, F&O double-downs, SIP discontinuations during drawdowns and the weight of a single negative headline. Includes Titan Biotech Ltd (BSE: 524717) FY25 audited educational case study.

May 21, 2026

Hero banner: dark blue page with the title 'Audit Committee Composition and Independence' and a FY21–FY25 milestone timeline showing green dots at Compliance, Disclosure, Audit clean, Board change, and All boxes.

Audit Committee Composition and Independence: SEBI LODR Regulation 18 and Companies Act Section 177(2)

How to read an Indian listed company's Audit Committee disclosure in 5 minutes — composition, financial-literacy, meeting-cadence, attendance and terms-of-reference tests, illustrated with Titan Biotech FY25 audited governance markers.

May 21, 2026

Hero section with the title 'Chuck Akre’s Three-Legged Stool' and subtitle 'The 25-Year Compounder Framework' on a dark blue background, featuring green accent lines and a 2x2 color grid labeled: Trader (gray), Compounder (green), Drift (light gray), Speculator (orange).

Chuck Akre’s Three-Legged Stool: The 25-Year Compounder Framework

Chuck Akre's three-legged stool — extraordinary business, exceptional management, glorious reinvestment runway — distils the compounder-picking framework. Titan Biotech's FY25 audited numbers map cleanly onto all three legs.

May 20, 2026

Hero header with dark blue gradient, large serif title 'The Outsiders Doctrine' and green italic subtitle, plus a centered multi-color donut chart labeled 'FY25 Reinvented' near the middle/bottom.

The Outsiders Doctrine: William Thorndike’s 2012 Study of Eight Unconventional CEOs and the Five Capital-Allocation Choices That Built ~20% Annual Shareholder Returns

William Thorndike's 2012 study of eight outsider CEOs revealed that compounding shareholder wealth is a capital-allocation discipline — not an operating one. Titan Biotech's FY25 audited numbers fit the five-choice template.